Home > Insider Trading > Filing (0001144204-17-029350)

Filing Details

Accession Number:: 0001144204-17-029350
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-05-24 16:34:27
Reporting Period:: 2017-05-22

Filing Date:: 2017-05-24
Accepted Time:: 2017-05-24 16:34:27
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1560241	G1 Therapeutics Inc.	GTHX	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1315082	Ra Capital Healthcare Fund Lp	C/O Ra Capital Management, Llc 20 Park Plaza, Suite 1200 Boston MA 02116	No	No	No	Yes
1346824	Ra Capital Management, Llc	20 Park Plaza, Suite 1200 Boston MA 02116	No	No	No	Yes
1384859	Peter Kolchinsky	C/O Ra Capital Management, Llc 20 Park Plaza, Suite 1200 Boston MA 02116	No	No	No	Yes

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-05-22	1,723,304	$0.00	1,723,304	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2017-05-22	560,940	$0.00	2,284,244	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2017-05-22	400,000	$15.00	2,684,244	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2017-05-22	5,169,916	$1.45	1,723,304	$0.00
Common Stock	Series C Preferred Stock	Disposition	2017-05-22	1,682,822	$2.97	560,940	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

These securities are held by RA Capital Healthcare Fund, L.P. (the "Fund").
RA Capital Management, LLC ("Adviser") is the general partner of the Fund and the investment adviser for a separately managed account (the "Account"). Peter Kolchinsky is the manager of Adviser. Adviser and Dr. Kolchinsky may be deemed indirect beneficial owners of the reported securities and disclaim beneficial ownership thereof: (A) in reliance on Rule 16a-1(a)(1)(v) and (vii); and (B) held by Fund, for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Adviser and Dr. Kolchinsky have no pecuniary interest in the reported securities held in the Account and disclaim: (A) beneficial ownership thereof for purposes of Rule 16a-1(a)(2); and (B) any filing obligations under Section 16 other than as a director by deputization and a director, respectively. This Form 4 shall not be construed as an admission that Adviser or Dr. Kolchinsky is or was under Section 16(a), or otherwise, the beneficial owner of any of the reported securities.
These securities include 453,801 shares held by the Fund and 107,139 shares held in the Account.
Each share of the Series B Preferred Stock converted into Common Stock on a 1-for-3 basis automatically upon the closing of the Issuer's initial public offering, and had no expiration date.
Each share of the Series C Preferred Stock converted into Common Stock on a 1-for-3 basis automatically upon the closing of the Issuer's initial public offering, and had no expiration date.
These securities include 322,895 shares held by the Fund and 77,105 shares held in the Account.
These securities include 2,500,000 shares held by the Fund and 184,244 shares held in the Account.
These shares are held by the Fund.
These securities include 1,361,403 shares held by the Fund and 321,419 shares held in the Account.